Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

[1]  S. Klein,et al.  Why does obesity cause diabetes? , 2022, Cell metabolism.

[2]  P. Hockings,et al.  Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging , 2021, Alimentary pharmacology & therapeutics.

[3]  C. Ayers,et al.  Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank. , 2021, Mayo Clinic proceedings.

[4]  B. Ludvik,et al.  Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial , 2021, The Lancet.

[5]  P. Joshi,et al.  Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. , 2021, The lancet. Diabetes & endocrinology.

[6]  A. Lonardo,et al.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials , 2021, Metabolites.

[7]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[8]  N. Stefan.  Causes, consequences, and treatment of metabolically unhealthy fat distribution. , 2020, The lancet. Diabetes & endocrinology.

[9]  K. Duffin,et al.  Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[10]  S. Ikramuddin,et al.  Nonalcoholic Steatohepatitis: A Review. , 2020, JAMA.

[11]  M. Coghlan,et al.  How May GIP Enhance the Therapeutic Efficacy of GLP-1? , 2020, Trends in Endocrinology & Metabolism.

[12]  K. Cusi,et al.  Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. , 2020, Journal of hepatology.

[13]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[14]  A. Gastaldelli,et al.  Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.

[15]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[16]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[17]  R. Gimeno,et al.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept , 2018, Molecular metabolism.

[18]  M. Nauck,et al.  Incretin hormones: Their role in health and disease , 2018, Diabetes, obesity & metabolism.

[19]  M. Roden,et al.  Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. , 2017, Clinical science.

[20]  K. Cusi,et al.  Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.

[21]  O. Chevallier,et al.  Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study , 2016, The Journal of clinical endocrinology and metabolism.

[22]  A. Chang,et al.  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[23]  P. Iozzo,et al.  Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study , 2016, Hepatology.

[24]  A. Jacquier,et al.  Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy , 2016, Diabetes, obesity & metabolism.

[25]  C. Sirlin,et al.  Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis , 2016, Therapeutic advances in gastroenterology.

[26]  J. Holst,et al.  Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans. , 2016, The Journal of clinical endocrinology and metabolism.

[27]  J. Holst,et al.  The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss , 2016, Nutrition & Diabetes.

[28]  S. Gough,et al.  Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis , 2016, Journal of hepatology.

[29]  J. D. De Guise,et al.  Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial , 2015, Diabetes Care.

[30]  A. Gamst,et al.  Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. , 2015, Radiology.

[31]  A. Canbay,et al.  Extrahepatic complications of nonalcoholic fatty liver disease , 2014, Hepatology.

[32]  M. Pirmohamed,et al.  Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists , 2012, PloS one.

[33]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[34]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[35]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.